

References for Table 2:

D835Y	[1-3]
D835V	[2-6]
ITD-D835Y	[7-10]
ITD-D835V	[7, 8, 11]

References for Figure 1.:

mutation	domain	Ref
S451	extracellular	[12]
ITD	JMD	[13]
Y572	JMD	[12]
F590	JMD	[14]
Y591	JMD	[14]
V592	JMD	[12, 14, 15]
F594	JMD	[14]
V579	JMD	[14]
ITD672	TKD1	[16]
N676	TKD1	[17, 18]
F691	TKD1	[18, 19]
G697	TKD1	[18]
D835	TKD2	[20]
I836	TKD2	[20]
R834	TKD2	[12]
D839	TKD2	[15]
S840	TKD2	[21]
Y842	TKD2	[22]
N841	TKD2	[23]

References for Figure 2.

Protein	Feature	Ref
FLT3	Y589, Y591, Y599, Y768, Y726, Y793, Y842, Y955	[24]
FLT3	Y842	[25]
SHP1	Y276, Y536, Y564	[25]
SHP2	Y279, Y551, Y584	[25]
SYK	Y203	[25]
SYK	Y525, Y526	[26]
SYK	Y352	[27]
PRKCAB	Y69	[25]
PLCG2	Y1217, Y759, Y351	[25]
SHIP	Y693, S423, S971	[27]
PTPN12	Y64	[25]
GAB1	Y659	[25]
GAB2	S141, Y293, Y614, S623, Y643	[27]
CCND3	expression	[28]
NFKBp105	S499, S759	[27]
RAD51	expression	[29]
RPS6KB1	T444	[27]
RPSA	Y139	[25]
RPS10	Y12, Y82	[25]
EIF1B	Y30	[25]
PIM1	expression	[28, 30]
PIM1	S99	[27]
Pu.1	expression	[31, 32]
MYC	expression	[28]
MYC	T58, S62, S64	[27]
C/EBPA	expression	[31, 32]
CEBPA	S21	[33]
P27Kip1	Y88	[34]
P27Kip1	S7, S10, S12	[27]
RAF1	S296	[27]
P38G	Y185	[25]
ERK1/2	Y204	[31]
ERK2	Y185, Y187	[25]
JAK2	Y570, Y1007	[25]
JAK2	Y570	[27]
STAT3	Y705	[25]
STAT3	S727	[27]
STAT5A	Y694	[25]
STAT5A	Y694	[29]
STAT5A	Y694, S780, S128	[27]
STAT5B	Y699	[25, 27]
TYK2	Y1054	[25]

PIM2	expression	[31, 32]
BclxL	expression	[29]
BAD	S118, S134, S99	[27]
BAD	S75, S99	[35]
PIK3R1	Y580	[27]
PIK3CD	S1039	[27]
BCAP	Y570	[25]
PTPRA	Y798	[25]
PIK3CA	S244	[27]
AKT	S473	[31]
GSK3A	S278, Y279, S282	[27]
SHP1	expression	[36]
Lyn	pY	[37]

Figure 3 references:

Figures created with KinMap [38], using data from:

<p>Figure 3 references:</p> <p>Figures created with KinMap [38], using data from:</p> <p>[39]</p> <p>[40]</p> <p>[41]</p>
--

Supplementary References S1:

1. Nguyen, B.; Williams, A. B.; Young, D. J.; Ma, H.; Li, L.; Levis, M.; Brown, P.; Small, D., FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors. *Oncotarget* **2017**, *8*, (7), 10931-10944.
2. Lee, L. Y.; Hernandez, D.; Rajkhowa, T.; Smith, S. C.; Raman, J. R.; Nguyen, B.; Small, D.; Levis, M., Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor. *Blood* **2017**, *129*, (2), 257-260.
3. Clark, J. J.; Cools, J.; Curley, D. P.; Yu, J. C.; Lokker, N. A.; Giese, N. A.; Gilliland, D. G., Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518. *Blood* **2004**, *104*, (9), 2867-72.
4. Barry, E. V.; Clark, J. J.; Cools, J.; Roesel, J.; Gilliland, D. G., Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. *Blood* **2007**, *110*, (13), 4476-9.
5. Yee, K. W.; Schittenhelm, M.; O'Farrell, A. M.; Town, A. R.; McGreevey, L.; Bainbridge, T.; Cherrington, J. M.; Heinrich, M. C., Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. *Blood* **2004**, *104*, (13), 4202-9.
6. Kampa-Schittenhelm, K. M.; Heinrich, M. C.; Akmut, F.; Dohner, H.; Dohner, K.; Schittenhelm, M. M., Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms. *Molecular cancer* **2013**, *12*, 19.
7. Smith, C. C.; Lin, K.; Stecula, A.; Sali, A.; Shah, N. P., FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. *Leukemia* **2015**, *29*, (12), 2390-2.
8. Warkentin, A. A.; Lopez, M. S.; Lasater, E. A.; Lin, K.; He, B. L.; Leung, A. Y.; Smith, C. C.; Shah, N. P.; Shokat, K. M., Overcoming myelosuppression due to synthetic lethal toxicity for FLT3-targeted acute myeloid leukemia therapy. *eLife* **2014**, *3*.
9. Baker, S. D.; Zimmerman, E. I.; Wang, Y. D.; Orwick, S.; Zatechka, D. S.; Buaboonnam, J.; Neale, G. A.; Olsen, S. R.; Enemark, E. J.; Shurtleff, S.; Rubnitz, J. E.; Mullighan, C. G.; Inaba, H., Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia. *Clin Cancer Res* **2013**, *19*, (20), 5758-68.
10. Ma, H. S.; Nguyen, B.; Duffield, A. S.; Li, L.; Galanis, A.; Williams, A. B.; Brown, P. A.; Levis, M. J.; Leahy, D. J.; Small, D., FLT3 kinase inhibitor TTT-3002 overcomes both activating and drug resistance mutations in FLT3 in acute myeloid leukemia. *Cancer research* **2014**, *74*, (18), 5206-17.
11. Smith, C. C.; Lasater, E. A.; Lin, K. C.; Wang, Q.; McCreery, M. Q.; Stewart, W. K.; Damon, L. E.; Perl, A. E.; Jeschke, G. R.; Sugita, M.; Carroll, M.; Kogan, S. C.; Kuriyan, J.; Shah, N. P., Crenolanib is a selective type I pan-FLT3 inhibitor. *Proceedings of the National Academy of Sciences of the United States of America* **2014**, *111*, (14), 5319-24.
12. Frohling, S.; Scholl, C.; Levine, R. L.; Loriaux, M.; Boggon, T. J.; Bernard, O. A.; Berger, R.; Dohner, H.; Dohner, K.; Ebert, B. L.; Teckie, S.; Golub, T. R.; Jiang, J.; Schittenhelm, M. M.; Lee, B. H.; Griffin, J. D.; Stone, R. M.; Heinrich, M. C.; Deininger, M. W.; Druker, B. J.; Gilliland, D. G., Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles. *Cancer cell* **2007**, *12*, (6), 501-13.
13. Nakao, M.; Yokota, S.; Iwai, T.; Kaneko, H.; Horiike, S.; Kashima, K.; Sonoda, Y.; Fujimoto, T.; Misawa, S., Internal tandem duplication of the *flt3* gene found in acute myeloid leukemia. *Leukemia* **1996**, *10*, (12), 1911-8.
14. Reindl, C.; Bagrintseva, K.; Vempati, S.; Schnittger, S.; Ellwart, J. W.; Wenig, K.; Hopfner, K. P.; Hiddemann, W.; Spiekermann, K., Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML. *Blood* **2006**, *107*, (9), 3700-7.

15. Janke, H.; Pastore, F.; Schumacher, D.; Herold, T.; Hopfner, K. P.; Schneider, S.; Berdel, W. E.; Buchner, T.; Woermann, B. J.; Subklewe, M.; Bohlander, S. K.; Hiddemann, W.; Spiekermann, K.; Polzer, H., Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia. *PLoS one* **2014**, *9*, (3), e89560.
16. Breitenbuecher, F.; Markova, B.; Kasper, S.; Carius, B.; Stauder, T.; Bohmer, F. D.; Masson, K.; Ronnstrand, L.; Huber, C.; Kindler, T.; Fischer, T., A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML. *Blood* **2009**, *113*, (17), 4063-73.
17. Heidel, F.; Solem, F. K.; Breitenbuecher, F.; Lipka, D. B.; Kasper, S.; Thiede, M. H.; Brandts, C.; Serve, H.; Roesel, J.; Giles, F.; Feldman, E.; Ehninger, G.; Schiller, G. J.; Nimer, S.; Stone, R. M.; Wang, Y.; Kindler, T.; Cohen, P. S.; Huber, C.; Fischer, T., Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain. *Blood* **2006**, *107*, (1), 293-300.
18. Cools, J.; Mentens, N.; Furet, P.; Fabbro, D.; Clark, J. J.; Griffin, J. D.; Marynen, P.; Gilliland, D. G., Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia. *Cancer research* **2004**, *64*, (18), 6385-9.
19. Verma, S.; Singh, A.; Kumari, A.; Pandey, B.; Jamal, S.; Goyal, S.; Sinha, S.; Grover, A., Insight into the inhibitor discrimination by FLT3 F691L. *Chemical biology & drug design* **2018**, *91*, (5), 1056-1064.
20. Thiede, C.; Steudel, C.; Mohr, B.; Schaich, M.; Schakel, U.; Platzbecker, U.; Wermke, M.; Bornhauser, M.; Ritter, M.; Neubauer, A.; Ehninger, G.; Illmer, T., Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. *Blood* **2002**, *99*, (12), 4326-35.
21. Spiekermann, K.; Bagrintseva, K.; Schoch, C.; Haferlach, T.; Hiddemann, W.; Schnittger, S., A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia. *Blood* **2002**, *100*, (9), 3423-5.
22. Kindler, T.; Breitenbuecher, F.; Kasper, S.; Estey, E.; Giles, F.; Feldman, E.; Ehninger, G.; Schiller, G.; Klimek, V.; Nimer, S. D.; Gratwohl, A.; Choudhary, C. R.; Mueller-Tidow, C.; Serve, H.; Gschaidmeier, H.; Cohen, P. S.; Huber, C.; Fischer, T., Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML). *Blood* **2005**, *105*, (1), 335-40.
23. Jiang, J.; Paez, J. G.; Lee, J. C.; Bo, R.; Stone, R. M.; DeAngelo, D. J.; Galinsky, I.; Wolpin, B. M.; Jonasova, A.; Herman, P.; Fox, E. A.; Boggon, T. J.; Eck, M. J.; Weisberg, E.; Griffin, J. D.; Gilliland, D. G.; Meyerson, M.; Sellers, W. R., Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. *Blood* **2004**, *104*, (6), 1855-8.
24. Razumovskaya, E.; Masson, K.; Khan, R.; Bengtsson, S.; Ronnstrand, L., Oncogenic Flt3 receptors display different specificity and kinetics of autophosphorylation. *Experimental hematology* **2009**, *37*, (8), 979-89.
25. Zhang, Y.; Askenazi, M.; Jiang, J.; Luckey, C. J.; Griffin, J. D.; Marto, J. A., A robust error model for iTRAQ quantification reveals divergent signaling between oncogenic FLT3 mutants in acute myeloid leukemia. *Molecular & cellular proteomics : MCP* **2010**, *9*, (5), 780-90.
26. Puissant, A.; Fenouille, N.; Alexe, G.; Pikman, Y.; Bassil, C. F.; Mehta, S.; Du, J.; Kazi, J. U.; Luciano, F.; Ronnstrand, L.; Kung, A. L.; Aster, J. C.; Galinsky, I.; Stone, R. M.; DeAngelo, D. J.; Hemann, M. T.; Stegmaier, K., SYK is a critical regulator of FLT3 in acute myeloid leukemia. *Cancer cell* **2014**, *25*, (2), 226-42.
27. Choudhary, C.; Olsen, J. V.; Brandts, C.; Cox, J.; Reddy, P. N.; Bohmer, F. D.; Gerke, V.; Schmidt-Arras, D. E.; Berdel, W. E.; Muller-Tidow, C.; Mann, M.; Serve, H., Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. *Molecular cell* **2009**, *36*, (2), 326-39.

28. Li, L.; Piloto, O.; Kim, K. T.; Ye, Z.; Nguyen, H. B.; Yu, X.; Levis, M.; Cheng, L.; Small, D., FLT3/ITD expression increases expansion, survival and entry into cell cycle of human haematopoietic stem/progenitor cells. *British journal of haematology* **2007**, *137*, (1), 64-75.
29. Bagrintseva, K.; Geisenhof, S.; Kern, R.; Eichenlaub, S.; Reindl, C.; Ellwart, J. W.; Hiddemann, W.; Spiekermann, K., FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L). *Blood* **2005**, *105*, (9), 3679-85.
30. Kim, K. T.; Baird, K.; Ahn, J. Y.; Meltzer, P.; Lilly, M.; Levis, M.; Small, D., Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. *Blood* **2005**, *105*, (4), 1759-67.
31. Choudhary, C.; Schwable, J.; Brandts, C.; Tickenbrock, L.; Sargin, B.; Kindler, T.; Fischer, T.; Berdel, W. E.; Muller-Tidow, C.; Serve, H., AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations. *Blood* **2005**, *106*, (1), 265-73.
32. Mizuki, M.; Schwable, J.; Steur, C.; Choudhary, C.; Agrawal, S.; Sargin, B.; Steffen, B.; Matsumura, I.; Kanakura, Y.; Bohmer, F. D.; Muller-Tidow, C.; Berdel, W. E.; Serve, H., Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations. *Blood* **2003**, *101*, (8), 3164-73.
33. Radomska, H. S.; Basseres, D. S.; Zheng, R.; Zhang, P.; Dayaram, T.; Yamamoto, Y.; Sternberg, D. W.; Lokker, N.; Giese, N. A.; Bohlander, S. K.; Schnittger, S.; Delmotte, M. H.; Davis, R. J.; Small, D.; Hiddemann, W.; Gilliland, D. G.; Tenen, D. G., Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. *The Journal of experimental medicine* **2006**, *203*, (2), 371-81.
34. Peschel, I.; Podmirseg, S. R.; Taschler, M.; Duyster, J.; Gotze, K. S.; Sill, H.; Nachbaur, D.; Jakel, H.; Hengst, L., FLT3 and FLT3-ITD phosphorylate and inactivate the cyclin-dependent kinase inhibitor p27(Kip1) in acute myeloid leukemia. *Haematologica* **2017**, *102*, (8), 1378-1389.
35. Kim, K. T.; Levis, M.; Small, D., Constitutively activated FLT3 phosphorylates BAD partially through pim-1. *British journal of haematology* **2006**, *134*, (5), 500-9.
36. Chen, P.; Levis, M.; Brown, P.; Kim, K. T.; Allebach, J.; Small, D., FLT3/ITD mutation signaling includes suppression of SHP-1. *The Journal of biological chemistry* **2005**, *280*, (7), 5361-9.
37. Okamoto, M.; Hayakawa, F.; Miyata, Y.; Watamoto, K.; Emi, N.; Abe, A.; Kiyoi, H.; Towatari, M.; Naoe, T., Lyn is an important component of the signal transduction pathway specific to FLT3/ITD and can be a therapeutic target in the treatment of AML with FLT3/ITD. *Leukemia* **2007**, *21*, (3), 403-10.
38. Eid, S.; Turk, S.; Volkamer, A.; Rippmann, F.; Fulle, S., KinMap: a web-based tool for interactive navigation through human kinome data. *BMC bioinformatics* **2017**, *18*, (1), 16.
39. Klaeger, S.; Heinzlmeir, S.; Wilhelm, M.; Polzer, H.; Vick, B.; Koenig, P. A.; Reinecke, M.; Ruprecht, B.; Petzoldt, S.; Meng, C.; Zecha, J.; Reiter, K.; Qiao, H.; Helm, D.; Koch, H.; Schoof, M.; Canevari, G.; Casale, E.; Depaolini, S. R.; Feuchtinger, A.; Wu, Z.; Schmidt, T.; Rueckert, L.; Becker, W.; Huenges, J.; Garz, A. K.; Gohlke, B. O.; Zolg, D. P.; Kayser, G.; Vooder, T.; Preissner, R.; Hahne, H.; Tonisson, N.; Kramer, K.; Gotze, K.; Bassermann, F.; Schlegl, J.; Ehrlich, H. C.; Aiche, S.; Walch, A.; Greif, P. A.; Schneider, S.; Felder, E. R.; Ruland, J.; Medard, G.; Jeremias, I.; Spiekermann, K.; Kuster, B., The target landscape of clinical kinase drugs. *Science (New York, N.Y.)* **2017**, *358*, (6367).
40. Karaman, M. W.; Herrgard, S.; Treiber, D. K.; Gallant, P.; Atteridge, C. E.; Campbell, B. T.; Chan, K. W.; Ciceri, P.; Davis, M. I.; Edeen, P. T.; Faraoni, R.; Floyd, M.; Hunt, J. P.; Lockhart, D. J.; Milanov, Z. V.; Morrison, M. J.; Pallares, G.; Patel, H. K.; Pritchard, S.; Wodicka, L. M.; Zarrinkar, P. P., A quantitative analysis of kinase inhibitor selectivity. *Nature biotechnology* **2008**, *26*, (1), 127-32.

41. Davis, M. I.; Hunt, J. P.; Herrgard, S.; Ciceri, P.; Wodicka, L. M.; Pallares, G.; Hocker, M.; Treiber, D. K.; Zarrinkar, P. P., Comprehensive analysis of kinase inhibitor selectivity. *Nature biotechnology* **2011**, 29, (11), 1046-51.